Regulatory Shifts for HCT/P Products Put Orthobiologics Manufacturers on the Spot

article image

FDA’s shift in regulations is forcing companies to decide how much they want to commit to orthobiologics and in what ways. Zimmer Biomet’s decision to double down on one product in the near term, while halting work on another, indicates how it and other firms are assessing their strategies. Senior Director Joel Higgins talks about the impact of the new regulations on the company’s choices.

Last November, FDA issued a long-awaited, final guidance on its standards for overseeing human cell and tissue products (HCT/P). It is the latest coda in a decades-long, ongoing effort by the agency to wrap its arms around the complex, evolving, and controversial area of tissue-based biologics and, by extension, the newer, fast-growing field of regenerative medicine.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: